BMI in Breast Cancer: Tailoring Adjuvant Chemotherapy
- A new meta-analysis identifies body mass index (BMI) as a predictor of chemotherapy side effects in early-stage breast cancer patients.
- Researchers from the GEICAM Breast Cancer Research Group and the International Trio Group have jointly analyzed data revealing a correlation between a patientS Body Mass Index (BMI) and...
- Specifically, the analysis showed that toxicities occurred in 5.5% of patients who were overweight, 5.9% of obese patients, and up to 9.3% of those with serious obesity.
“`html
BMI Linked to Chemotherapy Toxicity in Early-Stage Breast Cancer
Table of Contents
A new meta-analysis identifies body mass index (BMI) as a predictor of chemotherapy side effects in early-stage breast cancer patients.
Key Findings of the GEICAM and International Trio Group Study
Researchers from the GEICAM Breast Cancer Research Group and the International Trio Group have jointly analyzed data revealing a correlation between a patientS Body Mass Index (BMI) and the risk of meaningful toxicities when undergoing adjuvant chemotherapy with docetaxel for early-stage breast cancer. The study, published in the International Journal of Cancer, suggests that higher BMI is associated with increased risk of adverse effects.
Specifically, the analysis showed that toxicities occurred in 5.5% of patients who were overweight, 5.9% of obese patients, and up to 9.3% of those with serious obesity. This indicates a direct relationship between excess weight and the likelihood of experiencing significant side effects during docetaxel chemotherapy.
Implications for Treatment and Personalized medicine
“These findings are clinically relevant, since the BMI, an easily accessible variable, could help us choose the type of chemotherapy and thus improve the therapeutic approach to patients with initial breast cancer,” stated Dr.José Ángel García Sáenz, as reported by GEICAM. This suggests that a simple measurement like BMI could be incorporated into treatment planning to minimize adverse effects and maximize the benefits of chemotherapy.
The study highlights the growing trend towards personalized medicine in oncology, where treatment decisions are tailored to individual patient characteristics. BMI is a readily available and inexpensive metric that could contribute to a more individualized approach to breast cancer treatment.
About GEICAM and the International Trio Group
The GEICAM Research Group in Breast cancer, founded in 1995, is a non-profit organization leading academic breast cancer research in Spain. GEICAM has conducted over 170 studies involving more than 68,000 participants and currently comprises approximately 1,000 experts from over 200 Spanish hospitals. Its mission is to advance independent clinical, epidemiological, and translational research in oncology, promoting quality and a multidisciplinary approach to improve health outcomes, prevention, medical education, and knowledge dissemination.
The international Trio Group (Translational Research In Oncology) is a collaborative network focused on translational research in oncology,aiming to bridge the gap between laboratory discoveries and clinical applications.Further details about the International Trio Group is available on their official website.